Everolimus as second-line therapy for metastatic renal cell carcinoma: final results of phase IV study MARC-2. 2. Oktober 2018 M. Staehler, D. Christoph, M. Stöckle, J. Harde, A. Stenzl, D. Klein, I. Benz-Rüd, V. Grünwald, 2018. Oncol Res Treat 41 (suppl 4)(P610). Download Final results from IMPROVE: A randomized, controlled, open-label, cross-over phase IV study to determine the patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab for advanced HR+/HER2- breast cancer. Decker T, Söling U, Hahn A, Maintz C, Kurbacher CM, Rieger L, Chiabudini M, Falkenstein J, Runkel E, Potthoff K., 2018. Oncol Res Treat 41… Weiterlesen Vinorelbine plus everolimus versus vinorelbine monotherapy as second-line treatment for HER2-negative advanced breast cancer. Final results from the randomized phase II trial vicTORia. Decker, T., Marschner, N., Welt, A., Riedt, T., Hagen, V., Rauh, J., Klein, D., Potthoff, K., Jähnig, P., Schröder, H., Lerchenmüller, C., 2018. Oncol Res… Weiterlesen